Advanced technical frameworks in breast cancer brachytherapy: nanoparticle-enhanced dose optimization utilizing dual-source geant4 monte carlo simulations

Abstract

This invention presents an advanced brachytherapy system featuring a custom-designed dual-source catheter that integrates Iridium-192 (192Ir) and Cobalt-60 (60Co) for high-precision internal radiation therapy. The catheter is engineered with dual lumens and radiopaque markers to allow for spatial flexibility and accurate positioning. The system supports independent modulation of dwell time and source positioning, enhancing dose conformity and minimizing radiation exposure to surrounding healthy organs. Gold nanoparticles are employed within the tumor to amplify radiation via photoelectric interactions. Radial dose functions and anisotropy functions for both sources were evaluated using Geant4 Monte Carlo simulations, confirming high accuracy in dose distribution and angular coverage. These validated simulation results support optimal dose enhancement, safe delivery, and treatment personalization. This dual-source, nanoparticle-enhanced technique— supported by a novel catheter design—demonstrates significant improvements in dose metrics (e.g., D0.1cc and D2cc), offering a safe, precise, and versatile platform for treating a wide range of cancers.

Description

DescriptionTitle of Invention :

[0001] Advanced Technical Frameworks in Breast Cancer Brachytherapy:Nanoparticle-Enhanced Dose Optimization Utilizing Dual-Source Geant4 Monte Carlo SimulationsTechnical Field

[0002] This invention relates to cancer treatment, particularly brachytherapy for breast cancer.It introduces an advanced dual-source catheter system that guides two types of radioactive sources (A192Ir andA60Co) for optimized internal radiation delivery. The method enhances precision and effectiveness by integrating gold nanoparticles and using Monte Carlo simulations (Geant4) for planning. The invention improves dose conformity, reduces toxicity, and increases safety to surrounding healthy tissues.Background Art

[0003] Breast cancer remains one of the most prevalent malignancies globally, and its treatment requires techniques that maximize tumor control while minimizing exposure to surrounding healthy tissues. Volumetric Modulated Arc Therapy (VMAT) has become a common external beam radiation modality, delivering radiation doses with high precision through dynamic beam shaping and gantry rotation. While VMAT offers excellent dose conformity and shorter treatment durations, it can still result in unwanted radiation to critical organs such as the heart, lungs, and ribs — particularly in complex anatomical regions.

[0004] Brachytherapy, in contrast, allows for the placement of radioactive sources directly within or near the tumor, achieving steep dose gradients and improved sparing of surrounding tissue. However, conventional single-source brachytherapy, typically usingA192Ir orA60Co, faces challenges in simultaneously achieving deep tissue penetration and uniform dose distribution, especially for large or irregularly shaped tumors.

[0005] To address these limitations, the present invention introduces a novel dual-source brachytherapy system that combines the strengths of bothA192Ir andA60Co.A192Ir delivers localized, high-dose coverage, whileA60Co enhances deep tissue penetration. The innovation is further enhanced through the use of gold nanoparticles (GNPs), whichincrease the local dose via photoelectric and Compton interactions, thereby improving tumor control without increasing toxicity.

[0006] Compared to VMAT, this technique reduces radiation exposure to organs-at-risk. For example, simulations and dosimetric comparisons show a reduction of up to 16% in DO.lcc and D2cc for critical organs, highlighting improved therapeutic ratios. Additionally, this method allows for modulation of source dwell time and position, mimicking the dynamic capabilities of VMAT but within an internal delivery framework that offers greater precision and tissue sparing.

[0007] This dual-source, nanoparticle-enhanced brachytherapy approach thus offers a clinically advantageous alternative to VMAT for treating breast cancer and potentially other solid tumors.Summary of Invention

[0008] This invention presents a new brachytherapy method for treating breast cancer that improves how radiation is delivered inside the body. It uses two radioactive sources —A192Ir for targeting the tumor surface andA60Co for reaching deeper tissues. Both are placed through a specially designed dual-source catheter, which allows for better control over where and how the radiation is delivered.

[0009] To make the treatment even more effective, the system adds gold nanoparticles into the tumor area. These nanoparticles interact with the radiation to boost its intensity exactly where it’ s needed — inside the tumor — while keeping the surrounding healthy organs safe.

[0010] The planning and safety of the technique are confirmed using Monte Carlo simulations in Geant4, a powerful platform used for simulating radiation transport. This helps make sure that the radiation hits the tumor accurately, while protecting sensitive areas like the heart, lungs, and skin.

[0011] The invention also allows for modulating source position and dwell time, which means doctors can fine-tune the treatment to match each patient’s tumor shape and depth — similar to what VMAT does from the outside, but now from inside the body, with greater precision and less risk.

[0012] Overall, this method combines technology, biology, and physics to create a safer and more powerful treatment for breast cancer and possibly other types of cancer as well.

[0013] One of the main challenges in breast cancer radiotherapy is delivering enough radiation to destroy the tumor while protecting nearby healthy organs such as the heart, lungs, ribs, and skin. Existing methods like single-source brachytherapy or VMAT either lack deep dose penetration or increase radiation exposure to surrounding healthy tissues.

[0014] Traditional brachytherapy using a single source, such asA192Ir, often fails to deliver a balanced dose in both shallow and deep tumor regions, especially when the tumor is large or irregularly shaped. Conversely, although VMAT can shape radiation externally, it still carries risks of unwanted dose outside the target area and has limited adaptability to internal anatomical variations.

[0015] Another technical limitation is the rigidity of existing catheter designs, which are typically configuredTechnical Problem

[0016] One of the main challenges in breast cancer radiotherapy is delivering enough radiation to destroy the tumor while protecting nearby healthy organs such as the heart, lungs, ribs, and skin. Existing methods like single-source brachytherapy or VMAT either lack deep dose penetration or increase radiation exposure to surrounding healthy tissues.

[0017] Traditional brachytherapy using a single source, such asA192Ir, often fails to deliver a balanced dose in both shallow and deep tumor regions, especially when the tumor is large or irregularly shaped. Conversely, although VMAT can shape radiation externally, it still carries risks of unwanted dose outside the target area and has limited adaptability to internal anatomical variations.

[0018] Another technical limitation is the rigidity of existing catheter designs, which are typically configured for one source type and lack adjustable geometry. This limits the ability to personalize the treatment based on tumor location, depth, and patient- specific anatomy.

[0018] Furthermore, current systems generally do not utilize dose -enhancing agents like nanoparticles, nor do they include high-fidelity simulation tools such as Geant4 to predict radiation behavior and optimize dose delivery in real-time.

[0020] The present invention addresses these problems by introducing:

[0016] A dual-source system that enhances dose range and coverage control.

[0017] A specially designed catheter that allows source modulation in space and time.

[0018] The use of gold nanoparticles to locally amplify radiation within the tumor.

[0019] Geant4-based simulation tools for accurate, safe, and patient-specific treatment planning.Solution to Problem

[0020] To overcome the challenges of dose control, tissue protection, and treatment flexibility in breast cancer radiotherapy, the present invention introduces a dualsource brachytherapy system enhanced by gold nanoparticles and advanced simulation tools.

[0021] The invention utilizes two different radioactive sources:A192lr for shallow, localized dose delivery andA60Co for deeper tissue penetration. These sources are delivered through a custom dual-channel catheter that allows for independent movement and dwell-time modulation of each source.

[0022] The catheter is made from biocompatible material and includes radiopaque markers for accurate placement during imaging. Its design supports spatial and temporal modulation of the radiation, enabling more precise control over dose shaping in three dimensions.

[0023] Gold nanoparticles are introduced into the tumor area to enhance the radiation effect at the cellular level. These high-Z materials increase local energy absorption through photoelectric and Compton interactions, improving tumor kill rates while sparing healthy tissues.

[0024] Treatment plans are simulated and optimized using the Geant4 Monte Carlo platform, which accurately models radiation transport within human tissue. This ensures precise dose calculation, even in anatomically complex regions.

[0025] The combined approach of dual-source modulation, nanoparticle enhancement, and simulation-based planning offers a comprehensive solution to the limitations of existing radiotherapy techniquesAdvantageous Effects of Invention

[0026] The invention provides an advanced brachytherapy technique that improves treatment accuracy and safety for breast cancer patients. By combiningA192Ir andA60Co sources, the system offers better control over both shallow and deep dose delivery.

[0027] The dual-source configuration allows tailored dose distributions based on tumor size and depth, achieving superior conformity compared to single-source systems or external methods like VMAT.

[0028] The custom-designed catheter permits modulation of source positions and dwell times, enabling dynamic 3D dose shaping from inside the body with higher precision and reduced exposure to organs-at-risk.

[0029] The inclusion of gold nanoparticles within the tumor significantly enhances the therapeutic effect by amplifying local radiation through atomic interactions, while maintaining minimal impact on healthy tissues.

[0030] Geant4 Monte Carlo simulations ensure accurate planning and verification of dose delivery, leading to reduced risk of complications and improved overall treatment outcomes.

[0031] Comparative results showed reductions of up to 16% in high-dose metrics (D0.1cc and D2cc) for critical structures such as the heart, lungs, and ribs, validating the clinical potential of the invention.

[0032] The system is compatible with existing high-dose-rate (HDR) platforms, allowing practical integration into clinical workflows and expanding treatment options for complex cases.Brief Description of Drawings

[0033] Each figure in this invention was designed to support the technical claims and demonstrate the advantages of the proposed dual-source brachytherapy method:

[0034] Figure 1 was designed to show the complete structure of the custom dualsource catheter. It includes front, side, and 3D views to clearly visualize how theA192lr andA60Co sources are positioned and how radiopaque markers assist with imaging and placement.

[0035] Figure 2 was created to illustrate how gold nanoparticles are distributed in the tumor using a standard MIRD phantom model. This visual supports the dose enhancement concept introduced in the invention.

[0036] Figure 3 shows how radiation from theA60Co source spreads outward and in different directions (radial and anisotropic functions), validating the dose behavior through simulation.

[0037] Figure 4 complements Figure 3 by presenting how the angular dose fromA60Co changes with distance. This helps demonstrate dose stability at different tissue depths.

[0038] Figure 5 provides similar data for theA192lr source to confirm its dose distribution characteristics and validate the simulation model.

[0039] Figure 6 was designed to directly compare dose behavior between the two sources. It shows thatA192lr is better for surface-level targeting whileA60Co is more effective at deeper depths.

[0040] Figure 7 presents a merged anisotropy profile of both sources, showing how combining them results in better angular dose coverage — an essential point of the invention.

[0041] Figure 8 was included to compare the Dose Enhancement Factor (DEF) between different brachytherapy strategies — such as using one source, both sources, and the addition of nanoparticles — demonstrating the treatment’s efficiency.

[0042] Figure 9 was designed to show how the DEF changes with distance when gold nanoparticles are used. It confirms the enhancement is localized and quickly drops off, making the treatment safer for healthy tissueDescription of Embodiments

[0043] The present invention provides a novel brachytherapy system for cancer treatment, particularly breast cancer, using a dual-source catheter, gold nanoparticles, and Geant4-based dose simulation for optimized treatment planning and delivery.

[0044] In one embodiment, the system employs two radioactive sources:A192lr andA60Co. These are housed within a custom-designed dual-channel catheter made of biocompatible material, such as polyethylene or silicone. The catheter allows independent positioning and movement of the sources along predefined dwellpoints. Radiopaque markers embedded along the catheter provide accurate localization during CT or MRI imaging.

[0045] TheA192lr source is positioned for localized, high-precision radiation near the tumor surface, while theA60Co source targets deeper tumor regions. Both sources can be modulated in terms of dwell time and offset to optimize the dose distribution based on tumor shape, depth, and surrounding organs.

[0046] The system also incorporates the use of high-atomic-number nanoparticles, primarily gold (Au), which are distributed evenly throughout the tumor. These nanoparticles enhance local dose deposition through photoelectric and Compton effects, increasing tumor cell damage without affecting healthy tissues.

[0047] Treatment planning is conducted using Monte Carlo simulations implemented in the Geant4 platform. This allows for highly accurate modeling of radiation interactions within the patient's anatomy, including the presence of nanoparticles and variations in tissue composition.

[0048] The radial dose function and anisotropy function for both sources are simulated and validated against known reference data. These simulations confirm precise dose delivery and minimal deviation from expected values, ensuring clinical safety and efficacy.

[0049] Additional embodiments may include optimization algorithms to adjust source dwell times automatically based on 3D dose constraints, as well as compatibility with existing HDR brachytherapy systems.

[0050] The described configuration can be adapted for other cancers or anatomical sites requiring internal radiation with high dose precision and minimal toxicity. Examples

[0051] Example 1 - Dual-Source Dose SimulationA custom dual-channel catheter was modeled using the Geant4 Monte Carlo platform.A192lr andA60Co sources were positioned with predefined offsets and dwell times to optimize dose delivery across both superficial and deep tumor regions. Simulations in a MIRD phantom showed improved dose conformity compared to single-source techniques.

[0052] Example 2 - Nanoparticle Dose EnhancementGold nanoparticles (20 mg / g) were evenly distributed within the tumor volume. Their inclusion increased radiation absorption at the cellular level. Simulations showed a Dose Enhancement Factor (DEF) of up to 2.10 with dual-source irradiation, confirming localized dose amplification with minimal exposure to healthy tissues.

[0053] Example 3 - Dosimetric ComparisonRadial dose and anisotropy functions were calculated forA192lr,A60Co, and the combined dual-source configuration. Results demonstrated that the dual-source system improved angular uniformity and extended dose reach while maintaining conformity around the tumor boundary.

[0054] Example 4 - Organ SparingCritical structures including the heart, lungs, ribs, and skin were evaluated. Using dual sources with nanoparticle enhancement led to a significant reduction in D0.1cc and D2cc values — ranging from 11% to 16% — compared to single-source HDR brachytherapy, validating the approach’s protective effect on healthy tissues.

[0055] Example 5 - Application to Other OrgansThe technique was adapted for use in other anatomical sites. For cervical cancer,A1921 r was emphasized to minimize dose to the bladder and rectum. For deeper tumors such as those in the liver or pancreas,A60Co was paired with high- penetration isotopes likeA137Cs orA169Yb. Adjustments in source type, catheter geometry, and dwell timing allowed dose customization tailored to organ depth, shape, and clinical requirements.Industrial Applicability

[0056] The present invention is suitable for use in clinical radiation oncology, particularly in high-dose-rate (HDR) brachytherapy for various cancers, such as breast, cervical, prostate, liver, and pancreas

[0057] The dual-source system can be integrated into current HDR platforms with minimal changes. It improves dose precision and reduces radiation exposure to healthy tissue. The catheter is compatible with standard imaging tools and allows for time- and position-based source modulation.

[0058] The dosimetric analysis demonstrates the substantial progress attained by the integration of dual-source brachytherapy with nanoparticles. The comparison of dose rate constants for BEBIG 60Co and HDR 192lr sources reveals remarkable consistency, with Geant4 simulations producing a dose rate constant of 1.079 ± 0.008 cGy-h"1-LT1for 60Co and 1.099 ± 0.01 cGy-h"1-LT1for 192 Ir, exhibiting percentage differences between 0.73% and 1.54% relative to other Monte Carlo codes.

[0059] The dual-source technique, especially when combined with spatial and temporal modulation, achieves a maximum dose enhancement factor (DEF) of 2.10, outperforming single-source setups like 192lr (2.00) and 60Co (1.60).Critical organ dose was reduced significantly, including the contralateral breast (up to 16.06%), heart (up to 14.38%), lungs (up to 13.82%), and ribs (up to 13.20%). Skin dose reductions were minor and statistically insignificant, highlighting the importance of surface dose optimization

[0060] This system is clinically applicable, manufacturable with existing medical device technology, and offers a customizable and efficient treatment approach that enhances safety and therapeutic outcomes across multiple cancer types. Reference Signs ListReference to Deposited Biological Material

[0061] The present invention does not involve any deposited biological material.The catheter is made from non-biological, medical-grade materials such as silicone or polyethyleneSequence Listing Free Text

[0062] The present invention does not include any nucleotide or amino acid This section is not applicable.Citation List

[0063] [1] Arthur, D. W., et al. (2003). Partial breast brachytherapy after lumpectomy:Int J Radiat Oncol Biol Phys, 56, 681-689. https: / / doi.org / 10.1016 / S0360- 3016(03)00224-4

[0064] [2] Granero, D., et al. (2006). Dosimetric study of the lr-192 HDR Flexisource.Med Phys, 33(2), 457-463. https: / / doi.Org / 10.1118 / 1.2161405

[0065] [3] Hainfeld, J. F., et al. (2010). Gold nanoparticles enhance radiation therapy.Phys Med Biol, 55, 3045-3059. https: / / doi.org / 10.1088 / 0031-9155 / 55 / 11 / 004

[0066] [4] ICRP. (2007). Recommendations of the International Commission on Radiological Protection. ICRP Publication 103.https: / / doi.Org / 10.1016 / j.icrp.2007.10.003

[0067] [5] Jain, S., et al. (2012). Gold nanoparticles as novel agents for cancer therapy. Br J Radiol, 85(1010), 101-113. https: / / doi.org / 10.1259 / bjr / 59448833

[0068] [6] Palmans, H., et al. (2015). Future development of biologically relevant dosimetry. Br J Radiol, 88, 20140392. https: / / doi.org / 10.1259 / bjr.20140392

[0069] [7] Jones, B. (2022). Influence of hypoxia on LET and RBE. Phys Med Biol, 67, 125011.

[0070] [8] Sadeghi, M., et al. (2007). Dose distribution comparison for lr-192 sources.Radiat Phys Chem, 76, 177-185.https: / / d0i.0rg / l 0.1016 / j.radphyschem.2006.02.015

[0071] [9] Guzatov, D. V., et al. (2012). Plasmonic enhancement near silver nanoparticles. J Phys Chem C, 116(20), 10723-10733.https: / / d0i.0rg / l 0.1021 / jp3013676

[0072]

[0010] Valentin, J. (2003). ICRP Publication 92. Ann ICRP, 33(4), 1-121. https: / / doi.Org / 10.1016 / S0146-6453(03)00002-7

[0073] Patent Literature

[0074] NPL: US20100268198A1 - Describes a dual-lumen catheter for radiation therapy allowing simultaneous source placement to enhance dose control and spatial flexibility.

[0075] PTL2: WO2013161283A1 - Introduces methods and devices for delivering nanoparticles directly to tumors to increase the efficacy of radiation therapy.

[0076] PTL4: US20200123456A1 - Covers optimization algorithms for dwell time in multi-source brachytherapy systems, allowing more precise dose shaping.

[0077] PTL5: CN104321097A - Presents a catheter device tailored for intracavitary radiotherapy with high accuracy in placement and radiation delivery.Non Patent Literature

[0078] NPL1 : NPL1 : Arthur, D. W„ Zwicker, R. D„ & Koo, D. (2003). Partial breast brachytherapy after lumpectomy: Low-dose-rate and high-dose-rate experience. Int J Radiat Oncol Biol Phys, 56, 681-689. https: / / doi.org / 10.1016 / S0360- 3016(03)00224-4

[0079] NPL2: Granero, D., Perez-Calatayud, J., & Ballester, F. (2006). Dosimetric study of the lr-192 HDR Flexisource. Med Phys, 33(2), 457-463. https: / / d0i.0rg / l 0.1118 / 1.2161405

[0080] NPL3: Hainfeld, J. F„ Dilmanian, F. A., Zhong, Z„ et al. (2010). Gold nanoparticles enhance the radiation therapy of murine squamous cell carcinoma. Phys Med Biol, 55, 3045-3059. https: / / doi.org / 10.1088 / 0031-9155 / 55 / 11 / 004

[0081] NPL4: Jain, S., Hirst, D. G., & O'Sullivan, J. M. (2012). Gold nanoparticles as novel agents for cancer therapy. Br J Radiol, 85(1010), 101-113. https: / / d0i.0rg / l 0.1259 / bjr / 59448833

[0082] NPL5: ICRP. (2007). The 2007 Recommendations of the International Commission on Radiological Protection. ICRP Publication 103. https: / / d0i.0rg / l 0.1016 / j.icrp.2007.10.003

[0083] NPL6: Palmans, H., Rabus, H., Belchior, A., et al. (2015). Future development of biologically relevant dosimetry. Br J Radiol, 88, 20140392. https: / / doi.Org / 10.1259 / bjr.20140392

[0084] NPL7: Sadeghi, M., Hashemi, H., & Eneidi, R. (2007). Dose distribution comparison for various HDR lr-192 sources: Monte Carlo study. Radiat Phys Chem, 76, 177-185. https: / / doi.Org / 10.1016 / j.radphyschem.2006.02.015

[0085] NPL8: Jones, B. (2022). The influence of hypoxia on LET and RBE relationships with implications for ultra-high dose rates and FLASH modeling. Phys Med Biol, 67, 125011.

[0086] NPL9: Guzatov, D. V., Vaschenko, S. V., & Stankevich, V. V. (2012).Plasmonic enhancement of molecular fluorescence near silver nanoparticles: Theory, modeling, and experiment. J Phys Chem C, 116(20), 10723-10733. https: / / d0i.0rg / l 0.1021 / jp3013676

[0087] NPL10: Valentin, J. (2003). Relative biological effectiveness (RBE), quality factor (Q), and radiation weighting factor (wR): ICRP Publication 92. Ann ICRP, 33(4), 1-121. https: / / doi.org / 10.1016 / S0146-6453(03)00002-7

[0088]

Claims

Claims

1. A brachytherapy system comprising a dual-source catheter configured to accommodate two radioactive sources, namely lridium-192 (192lr) and Cobalt-60 (60Co), wherein the catheter permits independent spatial and temporal modulation of each source to optimize dose delivery to target tissue while minimizing exposure to surrounding healthy tissues.

2. The system of claim 1 , wherein the catheter comprises separate lumens or channels for each radioactive source, with calibrated source offsets to achieve differential dose penetration.

3. The system of claim 1 , further comprising radiopaque markers placed at predefined intervals along the catheter to facilitate precise imaging-guided placement using CT or MRL

4. The system of claim 1 , wherein gold nanoparticles are incorporated within or around the tumor volume to enhance the local radiation dose via increased photoelectric and Compton interactions.

5. The system of claim 1 , wherein the dose distribution is optimized using Geant4 Monte Carlo simulations to model photon transport, tissue interactions, and spatial dose distribution.

6. A method of delivering radiation therapy using the system of claim 1 , comprising positioning the dual-source catheter within or adjacent to the tumor site, and activating the radioactive sources in a sequential or alternating manner according to a pre-calculated treatment plan.

7. The method of claim 6, further comprising adjusting the dwell time and source position offsets for each radioactive source independently to conform the dose to the tumor shape and location.

8. The method of claim 6, further comprising administering gold nanoparticles at a concentration of 10-20 mg / g to the tumor site prior to radiation therapy.

9. The method of claim 6, wherein dose metrics such as D0.1 cc and D2cc to critical structures including heart, lungs, ribs, and skin are reduced by at least 10% compared to single-source brachytherapy techniques.

10. The system of claim 1, wherein the catheter materials are biocompatible and radiation-resistant, selected from polyethylene, polyurethane, or silicone.

11. The system of claim 1 , wherein the dual-source configuration is adaptable for treatment of various anatomical sites including breast, prostate, lung, liver, and gynecological tumors, with customizable catheter geometry and simulation-driven dose planning, i

Images